Decera Clinical Education Oncology Podcast
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast
Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc,
about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium.
Presenters:
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Virginia Kaklamani, MD, DSc
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A...
Advancing KRAS [LD1.1]G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions
In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including:
Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapyPresenters:
Luis Paz-Ares, MD, PhD
Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Madrid, Spain
Christine Bestvina, MD
Associate Professor
University of Chicago Medicine
Division...
Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies
In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including:
CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplantPresenters:
Ibrahim Aldoss, MD
Associate Professor
Division of Leukemia
Department of Hematology/HCT
City of Hope National Medical Center
Duarte, California
Bijal Shah, MD, MS
Senior Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida
Link to...
Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer
In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following:
Optimal KRAS mutation testing Emerging multiselective RAS inhibitors Combination strategiesPresenters:
Nilofer Azad, MD, FASCO
Professor of Oncology
Associate Director of Clinical Research
Sidney Kimmel Cancer Center at Johns Hopkins University
Co-Leader, Developmental Therapeutics Clinical Trials Group
Baltimore, Maryland
Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director, GI Oncology Program
UCLA School of Medicine
Los Angeles, California
Co...
Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer
Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer.
Presenters:
Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Denise Rouse, MS, PA-C
Physician Assistant
Th...
Individualized Hemophilia Care With Hemostatic Rebalancing Therapies
In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers.
Presenters:
Angela Weyand, MD
Associate Professor, Pediatric Hematology On...
Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET
In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including:
Personal insights and examples of the process of SDM with patients with PV or ETHow nuances of managing PV/ET influence SDMIndividualizing the process of SDMBarriers to effective SDMEducational resources for patients with PV, ET, or MPNsWorking with a team to incorporate SDM into clinical practiceProgram faculty:
Joan How, MD
Scientific and Medical Consultant
Clinical Chief of Hematology
Brigham a...
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:
Combination strategiesAdverse event managementWhere CELMoD agents may best fit within current and future treatment strategiesPresenters:
Jesus Berdeja, MD
Director of Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee
Amrita Krishnan, MD, FACP
Director, Judy and Bernard Center for Myeloma, City of Hope
Nason Hollingsworth Family Chair Myeloma
Executive Director, Hematology, City of Hope Ora...
PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting
In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:
Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Tre...Expert Highlights From the 2025 World Conference on Lung Cancer
In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).
Presenters:
John Heymach, MD, PhD
Chair and Professor
Department of Thoracic/Head and Neck Medical Oncology
Ruth Legett Jones Distinguished Chair
MD Anderson Cancer Center
Houston, Texas
Solange Peters, MD, PhD
Professor and Director of Medical Oncology
Department of Oncology
University Hospital of L...
PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting
In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:
MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary diseaseCARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogeneticsSTEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapyCAMMA1: Biomarker analyses f...PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting
In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:
CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLLBRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL EPCORE-FL-1: randomized phase III...PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting
In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including:
LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatmentAbstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapyAbstract 5: Deciphering the dilemma: intravenous (IV) iron u...PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting
In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:
Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AMLAbstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly...TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?
In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:
TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLCTIGIT-targeting agents: domvanalimab, rilvegostomigPresenters:
Benjamin Levy, MD, FASCO
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)
Washington, DC
Alex Spira, MD, PhD, FASCO
Director Clinical Research
Virginia Cancer Specialists
CEO N...
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:
Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selectionThe recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEONPresenters:
Rachel Grisham, MD
Section Head of Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Director G...
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:
Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancerResults of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant diseaseHow R-DXd may be incorporated into the treatment paradigmOther investigational CDH6-targeting ADCs: CUSP06, SIM0505Presenters:
Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB...
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care
In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including:
Trials of neoadjuvant immunotherapies demonstrating remarkable response rates with PD-(L)1 inhibitors such as cemiplimab, pembrolizumab, atezolizumab, and nivolumab with or without ipilimumabOngoing investigational efforts, including the phase III CLEAR CSCC study of intralesional immunotherapy and radiation-immunotherapy sequencingPresenters:
David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
...
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management
In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including:
The pathogenesis of PNH and the role of complement activationLandmark therapies such as eculizumab and ravulizumabAdvances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan)Quality-of-life considerations, treatment personalization, and emerging therapiesPr...
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on how to personalize adjuvant therapy for these patients. Supported by an educational grant from Lilly.
Faculty:
Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia
...
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer
In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare professional questions on how to personalize therapy for these patients. Supported by an educational grant from Lilly.
Faculty:
Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:
Brief overview of BTC and GEAApproved HER2-directed therapies for BTC and GEA and their mechanisms of actionEfficacy and toxicities of the approved agents and optimal management strategiesKey ongoing trials of HER2-directed therapies in BTC and GEAChallenges faced by healthcare professionals in the management of patients with BTC and/or GEAPresenters
Amit Mahipal, MD, MPH
Director, Gastrointestinal M...
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma
In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:
Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamabMonitoring and managing CRS and ICANS when prescribing bispecific...Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients
Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including:
How patients often present with disease-related symptomsTreatment selection considerations for the first-line and second-line settingHow to approach palliative care discussions with patientsEmerging therapies that are showing promise in this settingPresenters
Paul E. Oberstein, MD
Associate Professor of Medicine
Section Chief, GI Oncology
Perlmutter Cancer Center
NYU Langone Health
New York, New York
Mark O’Hara, MD
Associate Professor of Medicine
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma
In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.
LymphomasDLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCTFL: Tisa-cel (ELARA), axi-cel (ZUMA-5)MZL: Liso-cel (TRANSCEND FL)MCL: Real-world outcomes post brexu-celCLL: Liso-cel (TRANSCEND CLL 004)Multiple MyelomaCilta-cel (CARTITUDE-1)Anito-cel (iMMagine-1)GC012FArlo-celBMS-986453TriPRILPresenters:
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions
In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including:
Genomic testing options for assessing risk of recurrenceAdjuvant treatment duration and holidays with CDK4/6 inhibitorsManaging renal toxicities, prophylaxis for DVT, and asymptomatic ILDCDK4/6 inhibitors with inavolisib and fulvestrantPresenters:
William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois
Heather McArthur, MD, MPH...
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:
The clinical implications of using DLL3 as a therapeutic targetThe impact of emerging DLL3-targeted therapies on evolving treatment paradigmsHow to incorporate DLL3-based treatments into clinical practicePresenters:
Daniel Morgensztern, MD
Professor of Medicine
Clinical Director of Thoracic Oncology
Washington University School of Medicine
St Louis, Missouri
Jonathan Strosberg, MD
Professor
Department of GI Oncology
Moffitt Cancer Center and...
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective
In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:
Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedulesAvailable pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulationsCurrent and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerationsPresenters:
Kelly Romo, PharmD, BCOP
Manager, Oncology Medical Drug Management and Customer Initiatives
Blue Cross Blue Shield Michigan
Detroit...
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025
In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.
Program Abstracts:
POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:
Max S. Topp, MD
Head of...
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting
In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including:
DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic breast cancerASCENT-04/KEYNOTE-D19: phase III trial of first-line sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in PD-L1–positive advanced TNBCSERENA-6: phase III trial of ctDNA-guided switch to camizestrant plus CDK4/6i vs continued AI plus CDK4/6i following ESR1 mutation emergence in HR-positive/HER2-negative advanced bre...Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC
In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:
Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancerInteractive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancerOutcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and d...A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.
Presenters:
Eytan M. Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Eunice S. Wang, MD
Chief, Leukemia Service
Professor of Oncology
Department of Medicine
Roswell Park Comprehensive...
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:
The randomized phase III FLAIR trialThe randomized phase III SEQUOIA trialThe randomized phase III BRUIN CLL-321 trialPresenters:
James Davis, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
MUSC Hollings Cancer Center
Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University o...
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:
Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCCOverview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab) Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCC
Program faculty:
Joseph W. Franses, MD, PhD
Assistant Prof...
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies
In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 2025.
The Landscape of Frontline Options in HLSpecial Considerations for Older PatientsSpecial Considerations for Pediatric PatientsFuture Directions in HLPresenters:
Jonathan W. Friedberg, MD
Director, Wilmot Cancer Institute
Samuel Durand Professor of Medicine and Oncology
University of Rochester
Rochester, New...
Experts Discuss CELMoDs in Myeloma
In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including:
Mechanistic differences between CELMoDs and IMiDsEmerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myelomaThe clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myelomaPresenters:
Jesus Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee
Amrita Krishnan, MD, FACP
Director, Judy and Bernard B...
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities
In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:
Key Comorbidities in Patients with HR+/HER2- MBCImpact of PolypharmacyRole of APPs in Comprehensive CareRole of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBCUtility of RWE dataCommunicating Treatment Options With Patients and CaregiversUnderstanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of Life<...Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications
In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.
Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCsOn-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicityCombination Therapy Considerations: Challenges in combining ADCs with immunotherapy or chemotherapy due to overlapping toxicities and tolerability concernsPresenters:
Catherine Fahey...
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies
In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers.
Mechanisms of action of ADCs: how ADCs selectively deliver potent chemotherapy to tumor cellsClinical data across tumor types: highlights from recent trials with trastuzumab deruxtecan and exploration of emerging data on agents such as disitamab vedotinChallenges and future directions:key considerations for combining HER2-targeted ADCs with immunotherapy or chemotherapy, and sequencing ADC therapiesPresenters:
Cat...
How Pharmacists Can Enhance Comprehensive Patient-Centered Care for Patients With HR+/HER2- MBC and Comorbidities
In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:
Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:
https://bit.ly/4jCQe38
